Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3415244 in Patients With Advanced Solid Tumors
NCT03752177Phase 1Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2018
- Primary completion
- Oct 2019
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of LY3415244 in solid tumor (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Dose-Limiting Toxicities. Started Nov 2018; status: terminated.
02
Drugs
LY3415244
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03752177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03752177.